Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc > Trains Leaving The Station!!!

<< Previous

Bullboard Posts

Next >>

Comment by LFC1973on Dec 02, 2020 2:07pm

186 Views

Post# 32019212

RE:RE:Trains Leaving The Station!!!

Will be able to get them at the equivalent of 0.005 after the reverse split. It will consolidate at 0.01 and be worth 0.20, and then drop down to 0.10 within a week.

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale